Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 318 of 6351
-
Can a dash of spice and protein shield muscle during Weight-Loss shots?
Disease control Recruiting nowThis pilot study will examine whether daily protein supplementation with or without a mixture of culinary spices can help preserve muscle mass and function in adults who are using GLP-1 medications for weight management. The study will include 75 adults who recently started a GL…
Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new pill quiet stubborn chronic hives?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if different doses of TLL-018 works to treat in moderate-to-severe chronic spontaneous urticaria (CSU) participants . It will also learn about the safety of TLL-018. The main questions it aims to answer are: Which is the best regimen o…
Phase 2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Teaching the brain to tame pain: a virtual approach to enhance spinal cord stimulation
Symptom relief Not yet recruitingChronic pain is a leading cause of disability in the United States. When standard treatments fail, many patients develop treatment resistant pain and undergo Spinal Cord Stimulation (SCS) therapy. SCS uses an implanted device to send mild electrical currents to the spine to block…
Sponsor: University of Arkansas • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Can a new daily pill offer safer Long-Term control of schizophrenia?
Disease control Not yet recruitingThe primary purpose of this open-label phase 3 study is to evaluate the safety of HS-10380 on the incidence, severity, relationship to investigational product of adverse events (AE), serious adverse events (SAE), and adverse events leading to study drug discontinuationin Chinese …
Phase 3 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can new antibodies make dialysis safer by preventing clots without bleeding?
Disease control Not yet recruitingThis study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard anticoagulant treatment, such as heparin, to reduce …
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can board games sharpen minds in schizophrenia?
Symptom relief Not yet recruitingThis study aims to evaluate the effects of a scaffolding-based board game intervention on cognitive and functional outcomes in older adults with schizophrenia living in psychiatric nursing homes. Participants will be assigned by clusters to either an intervention group or a contr…
Sponsor: Kaohsiung Kai-Suan Psychiatric Hospital • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
Can a new injection plus a pill tame ulcerative colitis?
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HX15001 injection combined with Etrasimod tablets in participants with moderately to severely active ulcerative colitis (UC).
Phase 1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New radiation therapy targets Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug cocktail targets tough pancreatic tumors
Disease control Not yet recruitingThis phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with DS-8201a works for the treatment of pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for rare blood cancer: targeted drug enters final testing
Disease control Recruiting nowThis study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Magic mushroom compound tested for OCD in small trial
Symptom relief Not yet recruitingPrevious research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with OCD. The investigators propose to study 20 patients wi…
Phase 1/2 • Sponsor: Francisco A Moreno • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Can sleep therapy before a stem cell transplant boost quality of life?
Symptom relief Not yet recruitingThis proposed study is a prospective, randomized, controlled Phase 1 clinical trial to determine feasibility, acceptability (Aim 1) and preliminary effect (Aim 2) to mitigate insomnia symptoms and fatigue and improve health-related quality of life in patients who are planning to …
Phase 1 • Sponsor: University of Kansas Medical Center • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
New ER discharge plan aims to stop opioid overdose deaths
Disease control Not yet recruitingOpioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patie…
Phase 4 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One-Time drug infusion may shield the pancreas after ERCP
Prevention Not yet recruitingThe goal of this clinical trial is to learn if a single intravenous dose of tacrolimus, given before an ERCP procedure (an endoscopic procedure of the bile ducts and pancreas), can prevent post-ERCP pancreatitis (PEP) in adults at moderate-to-high risk of developing this complica…
Phase 4 • Sponsor: Amsterdam UMC, location VUmc • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
New drug aims to tame autoimmune hepatitis and cut steroid use
Disease control Not yet recruitingThe main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and glucocorticoid (GC) use in the management of AIH (Part 2…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can parents' online training curb teen depression and anxiety?
Prevention Not yet recruitingDepression and anxiety are common mental health problems among adolescents and can affect their relationships, education, physical health and everyday lives. In Pakistan, many adolescents experience emotional difficulties, but mental health problems are often overlooked. Stigma, …
Sponsor: Pakistan Institute of Living and Learning • Aim: Prevention
Last updated Aug 29, 2026 00:00 UTC
-
AI listens to the diaphragm to spot breathing pauses in premature babies
Diagnosis Not yet recruitingThe aim of this study is to monitor the frequency of apnoeas (pauses in breathing) on various methods of non-invasive respiratory support that are detected by an automated machine-learning (ML) model based on diaphragmatic electromyography (dEMG), in infants born at less than 32 …
Sponsor: King's College Hospital NHS Trust • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Can a pill tame severe eczema? a new trial puts QX-4533 to the test
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the safety and tolerability of QX-453, an investigational treatment, in healthy Chinese volunteers and patients with moderate-to-severe atopic dermatitis. The study will assess how the drug is absorbed and processed by the body, and …
Phase 1 • Sponsor: QuantX Biosciences, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new anesthetic shield the brain during tumor surgery?
Disease control Not yet recruitingPostoperative delirium and postoperative ischemic stroke are common neurological complications in clinical practice. The incidence of these complications is further increased in patients undergoing neurosurgical procedures. Intraoperative hypotension and burst suppression are hig…
Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Not yet recruitingThis study is open to adults with advanced or metastatic solid cancer, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. People can join…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC